Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 49, Issue 4, 2014, Pages 567-571

  Tessoulin, B ^a,b   Delaunay, J ^a,b,c   Chevallier, P ^a,b,c   Loirat, M ^a   Ayari, S ^a   Peterlin, P ^a   Le Gouill, S ^a,b,c,d   Gastinne, T ^a,c   Moreau, P ^a,b,c,d   Mohty, M ^a,b,c,d,e   Guillaume, T ^a,b,c  

^a CENTRE HOSPITALIER   (France)

^b Team 12   (France)

^c Centre D'Investigation Clinique en Cancérologie CI2C   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Allo HSCT; Azacitidine; Relapse

Indexed keywords

AZACITIDINE; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASIA; ARTICLE; BLEEDING; BONE MARROW CANCER; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; CLINICAL ARTICLE; COLON DISEASE; CONTROLLED STUDY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; ENTEROBACTERIACEAE INFECTION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INJECTION SITE RASH; KARYOTYPE; LUNG ASPERGILLOSIS; LUNG DISEASE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NUTRITIONAL DEFICIENCY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; SKIN INFECTION; SURVIVAL TIME; TREATMENT DURATION; VASOPLEGIA; VERY ELDERLY; WEAKNESS; ALLOTRANSPLANTATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AZACITIDINE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84897560646     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.233     Document Type: Article

References (27)

1. Mielcarek M, Storer BE, Flowers MED, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1160-1168.
2. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 1027-1032.
3. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36: 157-162.
4. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol Off 2002; 20: 405-412.
5. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483-493.
6. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol Off 2006; 24: 3895-3903.
7. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol Off 2010; 28: 562-569.
8. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012; 118: 1014-1022.
9. Frikeche J, Clavert A, Delaunay J, Brissot E, Gré goire M, Gaugler B et al. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. Exp Hematol 2011; 39: 1056-1063.
10. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza- 20-deoxycytidine. Lancet 1984; 2: 867-868.
11. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leuk Off J Leuk Soc Am Leuk Res Fund UK 2009; 23: 1019-1028.
12. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y et al. Cancertestis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 2011; 86: 918-922.
13. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918.
14. Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010; 115: 107-121.
15. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119: 3361-3369.
16. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010; 116: 129-139.
17. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
18. Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A et al. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graftversus- host response without overwhelming toxicity. Bone Marrow Transplant 2012; 47: 1112-1117.
19. Kim D-Y, Lee J-H, Park Y-H, Lee J-H, Kim S-D, Choi Y et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2012; 47: 374-379.
20. Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thé rapie- Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol Off 2012; 30: 4533-4540.
21. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599-1606.
22. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P et al. Lowdose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115: 1899-1905.
23. Lübbert M, Bertz H, Wäsch R, Marks R, Rüter B, Claus R et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45: 627-632.
24. Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010; 45: 872-876.
25. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leuk Off J Leuk Soc Am Leuk Res Fund UK 2013; 27: 1028-1036.
26. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leuk Off J Leuk Soc Am Leuk Res Fund UK 2013; 27: 1229-1235.
27. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leuk Off J Leuk Soc Am Leuk Res Fund UK 2012; 26: 381-389.